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Endothelial progenitor cells (EPCs) have been reported to
possess the capacity to colonize vascular grafts and hold
promise for therapeutic neovascularization. However, limited
quantities of EPCs have been the major factor impeding effec-
tive research on vasculoangiogenesis. In this study, cytokine
and culture conditions necessary for the provision of large
quantities of endothelial cells (ECs) were investigated. Cord
blood was collected from 18 normal full-term deliveries and
CD34+ cells were isolated by MACS system (Miltenyi
Biotech, Bergish-Gladbach, Germany). To evaluate the effect
of cytokines, CD34+ cells were cultured with various cytokine
combinations, such as stem cell factor (SCF), flt3-ligand (FL),
and thrombopoietin (TPO) with vascular endothelial growth
factor (VEGF), interleukin-1 , fibroblast growth factor-basic β
(FGF-b) as basic cytokines. The quantities of non-adherent and
adherent cells were the greatest with SCF, FL and TPO. The
addition of TPO to all other cytokines significantly increased
the number of non-adherent and adherent cells (p < 0.05,
Wilcoxon rank sum test). After four weeks of culture, adherent
cells expressed endothelial specific markers such as KDR,
CD31 and CD62E. Typical morphology of ECs was observed
during culture, such as cord-like structure and cobblestone
appearance, suggesting that the adherent cells were consistent
with ECs. In this study, the experimental conditions that opti-
mize the production of ECs for therapeutic neovascularization
were described. And it was possibly suggested that TPO plays
a major role in differentiation from EPCs to ECs.
Key Words : Endothellial progenitor cells, neovascularization,
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INTRODUCTION
Though neovascularization began as a concept
described by those investigating the pathogenesis
of diseases such as diabetic retinopathy and
rheumatoid arthritis, it is now widely studied by
people investigating tumor metastasis and treat-
ment of ischemic diseases.
1-3
Endothelial progenitor cells (EPCs) are known
to propagate the neovascularization process by
promoting vasculogenesis and angiogenesis. EPCs
have properties similar to those of embryonic an-
gioblasts, in that they have the capacity to
circulate, proliferate, and differentiate into mature
endothelial cells. However, they lack the ability to
form luminal characteristics of vasculogenesis and
do not possess mature endothelial markers.
4 In
fact, these cells share similar surface markers with
hematopoietic stem cells (HSCs), such as CD34,
Flk-1/KDR, Tie-1 and Tie-2 etc.
4-6
Studies of EPCs have been limited due to the
inability to obtain enough EPCs. HSCs make up
less than 1% of bone marrow cells and even a
smaller proportion of peripheral blood mono-
nuclear cells, and EPCs comprise less than 1% of
HSCs.
7,8 Therefore, techniques to isolate and cul-
ture the EPCs must be developed before they can
be used in the study of neovascularization and in
therapeutic protocols.
Asahara et al.
5 first described a method to iso-
late EPCs from human peripheral blood. Numer-
ous studies that characterized EPCs and at-
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tempted to optimize culture conditions with var-
ious growth factors and cytokines followed.
3,9,10
However, the isolation, identification, and char-
acterization of EPCs have been difficult due to
the absence of specific endothelial markers or
functional assays that differentiate EPCs from
HSCs.
4,9
The purpose of this study was to isolate EPCs
from cord blood and culture them in vitro to
observe the effects of various cytokines, such as
VEGF, IL-1 , FGF-b, SCF, FL and TPO on the β
development of EPCs to ECs, and finally, to
establish the technical and theoretical background
to allow the therapeutic use of EPCs.
MATERIALS AND METHODS
Cord blood collection
Umbilical cord blood was obtained from 18
normal full-term deliveries in Yonsei University
Medical Center and was placed into sterile blood
collection bags (Green Cross, Seoul, Korea) con-
taining 25 mL CPDA-1. Cord blood collection
was approved by the hospital ethics committee
and informed consent of the mother was ob-
tained.
Isolation of mononuclear cells and CD34+ cells
Unseparated cord blood was diluted 1 : 4 with
Hank's Balanced Salt Solution (HBSS, Gibco-BRL,
Grand Island, NY, USA), and mononuclear cells
(MNCs) were isolated using Ficoll-Hypaque (den-
sity, 1.077; Pharmacia Biotech, Uppsala, Sweden)
density centrifugation. MNCs recovered from the
interface were washed twice with HBSS and en-
umerated using hemocytometer. Thereafter, they
were resuspended in phosphate-buffered saline
(PBS), pH 7.4 (Sigma Chemical Co., St. Louis, MO,
USA). Uniform, magnetic beads (Miltenyi Biotech,
Bergish-Gladbach, Germany), which were coated
with a monoclonal antibody specific for human
CD34, were used to separate CD34+ cells. MNCs
were resuspended to a concentration of 1 × 10
8
cells in 300 L PBS, 5 μ mM EDTA. These cells were
incubated with beads at ratios that 100 L beads μ
per 10
8 cells for 15 minutes at 4 and processed
through a MACS magnetic separation column
(Miltenyi Biotech) to obtain purified CD34+ cells.
Selected CD34+ cells were detached from the
magnetic beads using the plunger and resus-
pended in Iscove's modified Dulbecco's medium
(IMDM).
Flow cytometry studies
For identification of HSCs, purified MNCs
were incubated with FITC-labeled anti-CD34
antibody (Becton Dickinson, San Jose, CA, USA),
PE-labeled anti-CD38 (Becton Dickinson) and
anti-CD117 (Pharmingen, San Diego, CA, USA)
antibodies. For EPCs, KDR-FITC (Sigma Chemi-
cal Co.) and AC133-PE (Miltenyi Biotech), CD31-
FITC (Pharmingen) and CD62E-PE (Pharmingen),
CD34-FITC and CXCR4-PE (Pharmingen) were
used. The percentage of positive cells was an-
alyzed by two-color flow cytometry (FACScan,
Becton Dickinson) and compared to IgG isotype
control.
Ex vivo expansion of CD34+ cells
CD34+ cells suspended in IMDM at 2 × 10
5cells/
mL were placed for culture into 24- or 96-well
microplates, that had been coated with 1 μg/mL
fibronectin, by 1 mL or 100 μL, respectively. The
media was supplemented with various cytokine
combinations, that is, 10 ng/mL of stem cell
factor (SCF), 10 ng/mL flt3-ligand (FL), and 5ng/
mL thrombopoietin (TPO) with 10 ng/mL vascular
endothelial growth factor (VEGF), 10 ng/mL IL-1
, 5 β ng/mL fibroblast growth factor-basic (FGF-
b) as the basic combination. Also, the culture
was performed in the presence or absence of
TPO with all other cytokines (VEGF, IL-1β, FGF-
b, SCF and FL) for 6 days to evaluate the effect
of TPO on EC development. On the 6th day of
culture, non-adherent cells were all removed,
and the number of non-adherent and adherent
cells obtained by culture with the different cyto-
kine combinations was compared. At this time,
non-adherent cells were collected after gentle
pipeting with PBS and adherent cells were
collected by treating PBS containing 5 mM EDTA
and harsh pipeting. Thereafter, the remaining
adherent cells were cultured in the presence ofJeong-Won Shin, et al.
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VEGF, IL-1β and FGF-b, that is, only under the
basic combination. Culture media was changed
every three days with fresh media supplemented
with the basic cytokines. On the 12th day of
culture, the number of adherent cells per mm
2
was counted using hemocytometer. During the
culture period, cells were recovered when they
reached 80% confluence, washed and enumer-
ated, then recultured in a 6-well plate or a 75
cm
2 flask.
The morphology of adherent cells was observed
every week of the culture period using an in-
verted microscope (Olympus Optical Co., LTD.,
Tokyo, Japan). After 4 weeks of culture, adherent
cells were recovered and analyzed for the
expression of EC markers by flow cytometry.
Statistical analysis
To assess the significance of TPO on EC de-
velopment, the Wilcoxon rank sum test was
applied using SPSS for windows release 8.0 (SPSS
Inc., Chicago, IL, USA). A p value of < 0.05 was
considered statistically significant.
RESULTS
Purification of CD34+ cells and flow cytometric
analysis
The average number of MNCs isolated from
each cord blood by Ficoll gradient centrifugation
was 1.34 (±0.43) × 10
8 and the average number of
CD34+ cells isolated by the MACS system was
4.22 (±2.46)×10
5. Analysis by two-color flow
cytometry found that, 0.65% of total MNCs were
CD34 positive. The recovery rate of CD34+ cells
by the MACS system was 84.04%. CD34+/CD38-
cells, considered to be primitive stem cells, made
up 0.05% of MNCs and 7.44% of CD34+ cells.
AC133+/KDR+ cells, considered to be EPCs, were
0.15% of MNCs and 1.73% of CD34+ cells (Table
1).
Comparison the number of suspension and ad-
herent cells cultured using various cytokine
combinations
The average number of non-adherent cells was
expanded to 5.9×10
4/mL after 6 days when CD34+
Table 1. Expressions of Surface Markers by the Mononuclear and CD34+ Cell Fractions Isolated from Cord Blood (n=7)
Surface marker
% positive (Mean ± SD)
Mononuclear cells CD34 selected cells
CD34+ 0.65 ± 0.19 84.04 ± 6.89
CD38+ 95.20 ± 1.94 89.65 ± 4.66
CD34+, CD38+ 0.63 ± 0.35 76.60 ± 7.49
CD34+, CD38-* 0.05 ± 0.05 7.44 ± 0.73
CXCR4+ 4.10 ± 2.38 4.55 ± 1.95
CD31+ 70.99 ± 12.7 88.37 ± 4.81
CD62E+ 2.69 ± 1.73 35.18 ± 3.82
CD117+ 4.34 ± 1.78 47.26 ± 14.9
AC133+ 0.61 ± 0.25 82.27 ± 10.8
KDR+ 0.18 ± 0.06 2.02 ± 1.55
AC133+, KDR+ 0.15 ± 0.08 1.73 ± 0.70
*surface markers for primitive stem cells.
surface markers for endothelial progenitor cells.
CD34+ fraction isolated by MACS system.Ex Vivo Expansion of Cord Blood EPCs
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cells were cultured only with the basic cytokines
(VEGF+IL-1 +FGF-b), that is, this represents a β
2.9-fold increase during the culture period. The
non-adherent cells were expanded to 5.4-, 3.7- and
4.2-fold when supplemented with SCF, FL and
TPO, respectively, in addition to the basic cyto-
kine combination. They were expanded to 7.1-fold
when supplemented with SCF+FL, 5.7-fold with
FL+TPO and 8.3-fold with SCF+TPO. When
supplemented with SCF+FL+TPO, the suspension
cells were expanded up to 21.1×10
4/mL, or 10.7-
fold after culture.
Adherent cells were counted at the 12th day of
culture. The average number of adherent cells was
5.6/mm
2 when cultured with the basic cytokines
(n=7). Adherent cell counts were 6.0, 10.7 and 15.9
cells/mm
2 when supplemented with SCF, FL and
TPO, respectively, in addition to the basic com-
bination. Adherent cell counts were 23.6, 27.1 and
37.9 cells/mm
2 when supplemented with SCF+
FL, FL+TPO and SCF+TPO, respectively. The
number of adherent cells was the greatest (65.4
cells/mm
2) when the media with basic cytokines
was supplemented with SCF+FL+TPO (Table 2).
Effect of thrombopoietin on the proliferation of
EPCs
To observe the effect of TPO on the prolife-
ration of EPCs, 2×10
5 CD34+ cells were cultured
in a 24-well microplate for 6 days in the presence
of TPO plus all the other cytokines. As a result of
the addition of TPO, the number of non-adherent
cells increased significantly (p=0.0341, Wilcoxon
rank sum test) (Fig. 1).
Surface marker analysis of ECs differentiated from
EPCs
KDR, CD31 and CD62E were found to be ex-
pressed on 13.3%, 14.7% and 18.4% of the adher-
ent cells cultured for 4 weeks. However, the
Table 2. Numbers of Adherent Cells Counted at the 12
th Day of Culture
Cytokine combinations Cell number per mm
2 (Mean±SD)
Basic (B)* 5.6 ± 4.5 4.0 ± 2.7
B+SCF 6.0 ± 4.2 4.7 ± 3.4
B+FL 10.7 ± 7.8 12.0 ± 6.7
B+TPO 15.9 ± 13.2 8.7 ± 7.1
B+SCF, FL 23.6 ± 12.1 12.3 ± 4.2
B+SCF, TPO 27.1 ± 12.3 18.9 ± 6.8
B+FL, TPO 37.9 ± 19.9 17.3 ± 7.9
B+SCF, TPO, FL 65.4 ± 23.1 33.1 ± 12.0
*VEGF+FGF-b+IL-1 . β
cell count per mm
2.
Fig. 1. The numbers of non-adherent cells obtained from
cultures preformed with or without TPO in the presence
of VEGF, IL-1 , FGF-b, SCF and FL in 24-well micro β -
plates (n=9). The line represents the mean values. The
addition of TPO significantly increased the numbers of
non-adherent cells (p < 0.05, Wilcoxon rank sum test).Jeong-Won Shin, et al.
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frequencies of adherent cells expressing CD34 and
AC133 were only 0.4% and 0.0%, compared to
84.0% and 82.3% before culture. The expression of
CXCR-4 (CD183) on adherent cells after 4 weeks
of culture was also 0.0% (Fig. 2).
Morphologic changes of adherent cells during
the culture period
Initially, most cells were small and round, but
within 24 hours of culture, the cells promptly
attached to the wells and became spindle shaped.
At about the 3rd day of culture, the cells formed
several cell clusters. Cord-like structures resem-
bling the first stages of vasculogenesis appeared
as early as 7 days of culture and the characteristic
endothelial cobblestone colonies were observed at
about 4 weeks of culture (Fig. 3).
DISCUSSION
EPCs, the cells initiating neovascularization, ex-
press similar endothelial-specific markers as ma-
ture ECs, including flk-1/KDR (VEGFR-2), Tie-1,
Tie-2 and VE-cadherin. Furthermore, EPCs share
similar markers with HSC, such as VEGFR-1,
CD34, CD31 (platelet endothelial cell adhesion
molecule, PECAM), Tie-1, Tie-2 and von Wille-
brand factor.
11-13 However, the isolation and char-
acterization of EPCs from blood have been diffi-
cult because of the absence of specific phenotypic
markers and functional assays to define them.
4
Asahara et al.
5 first isolated EPCs from peri-
pheral blood using CD34 and KDR as markers
and they found that 10.8 ± 0.9% of peripheral
blood were EPCs, coexpressing CD34 and KDR.
On the other hand, Peichev et al.
4 identified EPCs
from cord blood, fetal liver and G-CSF mobilized
peripheral blood using AC133 and KDR and
found that 1.4 ± 0.5% of cord blood, 1.2 ± 0.3% of
fetal liver and 2.0 ± 0.5% of G-CSF mobilized
peripheral blood were EPCs, which was much less
than that of Asahara et al.
5 Peichey et al.
4 believed
that this difference may be due to the use of a
highly specific monoclonal antibody to the extra-
cellular domain of KDR in their study, allowing
for the more accurate measurement of EPCs, as
compared to the polyclonal antibody directed to
the intracellular domain of KDR used by Asahara
et al.
5 In our study, we isolated CD34+ cells from
cord blood and identified EPCs using monoclonal
antibodies to the AC133 and KDR, and found that
1.73 ± 0.7% of the cells coexpressing both markers.
This result was similar to that of Peichev's.
4
AC133, a new hematopoietic stem cell marker,
identifies a structurally novel 5-transmembrane
antigen that is expressed on a large subset of
Fig. 2. Flow cytometric analysis of endothelial cells obtained from CD34+ cells after 4 weeks of culture. The dark line
identifies the cells labeled with isotype control antibody and the faint line identifies the cells labeled with antibodies specific
for the surface markers. Cultured cells were positive for KDR, CD31 and CD62E, but negative for CD34, CD117, AC133
and CXCR4 (cut off, 10%).Ex Vivo Expansion of Cord Blood EPCs
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EPCs and HSCs, but not on the mature endothe-
lium.
14-16 Peichev et al.
4 demonstrated that CD34+
cells coexpressing AC133 and KDR are function-
ally non-adherent endothelial cells that have the
capacity to migrate and differentiate into mature
adherent endothelial cells expressing KDR, but
not AC133. Our study also found that cultured
adherent cells expressed KDR (13.3%), but not
AC133 (0.0%), also suggesting that non-adherent
EPCs coexpressing AC133 and KDR had differen-
tiated into mature adherent ECs.
In our study, EPCs were estimated to make up
1.73% of CD34+ cells in cord blood, that is, 7.3 ×
10
3 EPC cells per cord blood collection. Since the
number of ECs in each cord blood unit was so low
it was impossible to characterize the EPCs prior
to culture because at least 1 × 10
6 cells were
needed to analyze their surface markers by flow
cytometry.
17 Accordingly, we induced the ex vivo
expansion and differentiation of EPCs by cul-
turing them with various combinations of SCF,
FL, TPO with VEGF, IL-1β, FGF-b as the basic
cytokines. At the same time, we analyzed the
optimal cytokine conditions required to induce
the ex vivo expansion of EPCs. We found that the
number of non-adherent cells was the greatest
when the media supplemented with SCF, FL and
TPO. Interestingly, however, non-adherent cells
coexpressing CD34 and KDR were not detected by
flow cytometry after 6 days of culture (data not
shown). It was thought that HSCs containing
EPCs had already begun to differentiate to their
respective hematopoietic cell lineages, and this
differentiation was accelerated by the cytokines
added during culture. Therefore, to find the
optimal cytokine conditions for the differentiation
of EPCs to ECs, we made use of the cell adhe-
siveness that characterizes ECs. The number of
adherent cells was also the greatest when the
media was supplemented with SCF, FL and TPO.
TPO is known to stimulate VEGF release from
hematopoietic progenitors and each cell lineage.
18
In our study, the number of non-adherent cells
was compared after cultured with or without TPO
in the presence of all other cytokines and we
found that TPO contributed significantly to the
Fig. 3. Morphology of cord blood derived adherent cells at days 7(A), 14(B), 21(C), and 28(D) of in vitro culture. A) and
B) Cord-like structures resembling the first stages of vasculogenesis; C) and D) Characteristic endothelial cobblestone
colonies (Unstained; magnification, × 100).Jeong-Won Shin, et al.
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self-renewal and differentiation of EPCs.
Asahara et al.
5 compared the expression of leu-
kocyte and EC markers between CD34+ cells
isolated from fresh peripheral blood (MBCD34+)
and adherent cells produced by the culture of
MBCD34+ on fibronectin for 7 days (ATCD34+).
In freshly isolated MBCD34+ cells, 15.7% were
CD34+, 94.1% were CD45+, 51.3% were CD31+,
27.6% were KDR+, 30.3% were Tie-2+ and 0.6%
were CD62E+. In ATCD34+ cells, 32.8% were
CD34+, 27.2% were CD45+, 71.5% were CD31+,
35.9% were KDR+, 54.6% were Tie-2+ and 9.0%
were CD62E+. Peichev et al.
4 compared the ex-
pression of several HSC and EC markers by EPC,
EC and IL-1β activated EC. They found that KDR,
VE-cadherin, CD31 and CD117 were expressed by
both EPCs and ECs, but AC133 was expressed
only by EPCs. The expression of most markers by
IL-β activated ECs was similar to ECs, but CD62E
was expressed by IL-β activated ECs but not by
EPCs and ECs.
CXCR-4, the natural receptor for the chemokine
SDF-1, is expressed on endothelial cells. CXCR-4
knock-out mice are not viable and have multiple
defects, including angiogenesis, suggesting that
this receptor may play a role in vascular remo-
deling and, possibly, trafficking of circulating
endothelial progenitor cells.
4
In our study, adherent cells cultured for 4 weeks
expressed EC specific markers such as KDR, CD31
and CD62E though the expression was weak, but
did not express CD34, CD117, AC133 and CXCR4.
EC markers may have been suppressed secondary
to the effect of cytokines used in culture. It is also
possible that cell surface antigens were destroyed
by the cell scraper used to detach adherent cells
for flow cytometric analysis.
The adherent cells not only expressed typical
EC antigens, but during the culture period they
showed the typical morphologies of endothelial
cells, such as the cord-like structure and cobble-
stone appearance. This provides further evidence
that the adherent cells were consistent with ECs.
4-6
In conclusion, we describe experimental condi-
tions that optimize the production of ECs and that
could be used to obtain large numbers of ECs for
therapeutic neovascularization. We also charac-
terized the EPCs in CD34+ cells isolated from cord
blood and confirmed that TPO plays a major role
in the differentiation from EPCs to ECs.
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